JP2021019589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021019589A5 JP2021019589A5 JP2020155809A JP2020155809A JP2021019589A5 JP 2021019589 A5 JP2021019589 A5 JP 2021019589A5 JP 2020155809 A JP2020155809 A JP 2020155809A JP 2020155809 A JP2020155809 A JP 2020155809A JP 2021019589 A5 JP2021019589 A5 JP 2021019589A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- isolated cell
- seq
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977751P | 2014-04-10 | 2014-04-10 | |
| US61/977,751 | 2014-04-10 | ||
| US201461986479P | 2014-04-30 | 2014-04-30 | |
| US61/986,479 | 2014-04-30 | ||
| US201462058973P | 2014-10-02 | 2014-10-02 | |
| US62/058,973 | 2014-10-02 | ||
| US201462088363P | 2014-12-05 | 2014-12-05 | |
| US62/088,363 | 2014-12-05 | ||
| US201462089730P | 2014-12-09 | 2014-12-09 | |
| US62/089,730 | 2014-12-09 | ||
| US201462090845P | 2014-12-11 | 2014-12-11 | |
| US62/090,845 | 2014-12-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561659A Division JP6765968B2 (ja) | 2014-04-10 | 2015-04-08 | 薬物制御による導入遺伝子の発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021019589A JP2021019589A (ja) | 2021-02-18 |
| JP2021019589A5 true JP2021019589A5 (enExample) | 2021-07-26 |
| JP7093385B2 JP7093385B2 (ja) | 2022-06-29 |
Family
ID=54288361
Family Applications (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561839A Pending JP2017515464A (ja) | 2014-04-10 | 2015-04-08 | 細胞免疫療法のための方法および組成物 |
| JP2016561722A Active JP6772068B2 (ja) | 2014-04-10 | 2015-04-08 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2016561635A Active JP6765967B2 (ja) | 2014-04-10 | 2015-04-08 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2017504604A Active JP6788573B6 (ja) | 2014-04-10 | 2015-04-08 | メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造 |
| JP2016561659A Active JP6765968B2 (ja) | 2014-04-10 | 2015-04-08 | 薬物制御による導入遺伝子の発現 |
| JP2020105133A Active JP7062720B2 (ja) | 2014-04-10 | 2020-06-18 | 細胞免疫療法のための方法および組成物 |
| JP2020155809A Expired - Fee Related JP7093385B2 (ja) | 2014-04-10 | 2020-09-16 | 薬物制御による導入遺伝子の発現 |
| JP2020155429A Active JP7148580B2 (ja) | 2014-04-10 | 2020-09-16 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2020164326A Active JP7106610B2 (ja) | 2014-04-10 | 2020-09-30 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022069142A Active JP7542270B2 (ja) | 2014-04-10 | 2022-04-20 | 細胞免疫療法のための方法および組成物 |
| JP2022112278A Active JP7402933B2 (ja) | 2014-04-10 | 2022-07-13 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022150928A Active JP7508516B2 (ja) | 2014-04-10 | 2022-09-22 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561839A Pending JP2017515464A (ja) | 2014-04-10 | 2015-04-08 | 細胞免疫療法のための方法および組成物 |
| JP2016561722A Active JP6772068B2 (ja) | 2014-04-10 | 2015-04-08 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2016561635A Active JP6765967B2 (ja) | 2014-04-10 | 2015-04-08 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2017504604A Active JP6788573B6 (ja) | 2014-04-10 | 2015-04-08 | メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造 |
| JP2016561659A Active JP6765968B2 (ja) | 2014-04-10 | 2015-04-08 | 薬物制御による導入遺伝子の発現 |
| JP2020105133A Active JP7062720B2 (ja) | 2014-04-10 | 2020-06-18 | 細胞免疫療法のための方法および組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155429A Active JP7148580B2 (ja) | 2014-04-10 | 2020-09-16 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
| JP2020164326A Active JP7106610B2 (ja) | 2014-04-10 | 2020-09-30 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022069142A Active JP7542270B2 (ja) | 2014-04-10 | 2022-04-20 | 細胞免疫療法のための方法および組成物 |
| JP2022112278A Active JP7402933B2 (ja) | 2014-04-10 | 2022-07-13 | 導入遺伝子の遺伝子タグおよびその使用方法 |
| JP2022150928A Active JP7508516B2 (ja) | 2014-04-10 | 2022-09-22 | 特定の組成を有する遺伝子により改変されたｔ細胞製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (12) | US20170029774A1 (enExample) |
| EP (8) | EP3954708A1 (enExample) |
| JP (12) | JP2017515464A (enExample) |
| KR (8) | KR102730216B1 (enExample) |
| CN (7) | CN112877291A (enExample) |
| AU (8) | AU2015243920B2 (enExample) |
| BR (3) | BR112016023500B1 (enExample) |
| CA (4) | CA2945320A1 (enExample) |
| ES (2) | ES2880932T3 (enExample) |
| IL (5) | IL297591B2 (enExample) |
| MX (6) | MX2016013149A (enExample) |
| MY (4) | MY185678A (enExample) |
| NZ (3) | NZ725079A (enExample) |
| PH (4) | PH12016502011B1 (enExample) |
| RU (5) | RU2751921C2 (enExample) |
| SA (1) | SA516380056B1 (enExample) |
| SG (8) | SG10201808825XA (enExample) |
| WO (5) | WO2015157386A1 (enExample) |
| ZA (3) | ZA201607060B (enExample) |
Families Citing this family (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100548667C (zh) * | 2003-01-20 | 2009-10-14 | 日本瑞翁株式会社 | 层合件及其制造方法 |
| EP3653212B1 (en) | 2012-12-20 | 2023-04-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG11201603484PA (en) * | 2013-11-21 | 2016-05-30 | Ucl Business Plc | Cell |
| CN112877291A (zh) * | 2014-04-10 | 2021-06-01 | 西雅图儿童医院 (Dba西雅图儿童研究所) | 基因修饰的t细胞产品、其制备方法和用途 |
| ES2995052T3 (en) | 2014-04-23 | 2025-02-05 | Juno Therapeutics Inc | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| GB2540694A (en) | 2014-04-29 | 2017-01-25 | Seattle Children's Hospital (Dba Seattle Children's Res Institute) | CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies |
| EP3209690B1 (en) | 2014-10-20 | 2021-05-05 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
| AU2015339743C1 (en) | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| EP3227323B1 (en) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| CA2969877A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| AU2016206457B2 (en) | 2015-01-16 | 2021-11-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
| US10808230B2 (en) | 2015-02-24 | 2020-10-20 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified T cells |
| KR102632082B1 (ko) | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| IL303972A (en) * | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
| JP6961497B2 (ja) | 2015-06-25 | 2021-11-05 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| HK1256087A1 (zh) | 2015-08-07 | 2019-09-13 | Seattle Children's Hospital, Dba Seattle Children's Research Institute | 用於实体瘤靶向的双特异性cart细胞 |
| KR102789429B1 (ko) * | 2015-09-22 | 2025-03-31 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 림프구에 유전자를 고 수준으로 안정적으로 전달하는 방법 |
| RU2759879C2 (ru) | 2015-10-06 | 2021-11-18 | Сити Оф Хоуп | Химерные рецепторы антигена, нацеленные на psca |
| CN108463228A (zh) * | 2015-10-23 | 2018-08-28 | 科罗拉多大学董事会法人团体 | 鳞状细胞癌的预后和治疗 |
| HK1254836A1 (zh) | 2015-10-30 | 2019-07-26 | Nbe-Therapeutics Ag | 抗-ror1抗体 |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN108603200B (zh) * | 2015-11-23 | 2022-08-19 | 诺华股份有限公司 | 优化的慢病毒转移载体及其用途 |
| CA3004665C (en) * | 2015-12-14 | 2021-08-24 | GenomeFrontier Therapeutics, Inc. | Transposon system, kit comprising the same, and uses thereof |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| MX2018008926A (es) | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Composiciones de anticuerpo contra ror1 y métodos relacionados. |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| WO2017161212A1 (en) | 2016-03-16 | 2017-09-21 | Juno Therapeutics, Inc. | Methods for adaptive design of a treatment regimen and related treatments |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US12060394B2 (en) | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| SG10202012157QA (en) | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| JP7591342B2 (ja) * | 2016-06-08 | 2024-11-28 | プレシゲン，インコーポレイテッド | Ｃｄ３３特異的キメラ抗原受容体 |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| US20190119636A1 (en) * | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| WO2018075941A1 (en) * | 2016-10-21 | 2018-04-26 | Washington University | Ap4 and methods of promoting t cell activation |
| KR20190090390A (ko) * | 2016-11-30 | 2019-08-01 | 인트렉손 코포레이션 | 스테로이드 투여 및 면역요법 |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| CN106800601B (zh) * | 2017-01-19 | 2021-04-06 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| ES2988795T3 (es) | 2017-02-27 | 2024-11-21 | Juno Therapeutics Inc | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| JP7359751B2 (ja) | 2017-03-14 | 2023-10-11 | ジュノー セラピューティクス インコーポレイテッド | 極低温保管のための方法 |
| CN106963945A (zh) * | 2017-03-27 | 2017-07-21 | 山东兴瑞生物科技有限公司 | 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗 |
| US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN108728477B (zh) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | 一种高效的转座突变系统及构建方法 |
| EP4613864A2 (en) * | 2017-05-17 | 2025-09-10 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| JP7039623B2 (ja) * | 2017-05-26 | 2022-03-22 | グリーン・クロス・ラブ・セル・コーポレイション | 形質転換されたｔ細胞を用いてナチュラルキラー細胞を培養する方法 |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| EP3641768B1 (en) | 2017-06-21 | 2025-12-31 | iCell Gene Therapeutics LLC | Chimeric Antigen Receptors (CARs), Compositions and Associated Methods |
| CN107335054B (zh) * | 2017-06-30 | 2021-01-15 | 山东兴瑞生物科技有限公司 | 一种慢性乙肝治疗性dc疫苗 |
| EP3665193A1 (en) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| WO2019032942A1 (en) * | 2017-08-11 | 2019-02-14 | Tribiotica Llc | METHODS OF GENERATING EPITOPES FOR BONDING TO RECONNAISSANCE MOLECULES BY ASSEMBLING ON TEMPLATES |
| SG11202001011XA (en) * | 2017-08-23 | 2020-03-30 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind cxcr5 |
| CN111433354A (zh) * | 2017-09-26 | 2020-07-17 | 朗沃德大学 | 作为免疫疗法的pd1特异性嵌合抗原受体 |
| KR20250010043A (ko) | 2017-10-18 | 2025-01-20 | 프레시전 인코포레이티드 | 스페이서를 포함하는 폴리펩타이드 조성물 |
| CN107759700A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd19抗原的转基因t细胞及其制备方法与应用 |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR20200074997A (ko) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체 |
| KR102845789B1 (ko) | 2017-11-01 | 2025-08-14 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
| WO2019089855A1 (en) * | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US12193994B2 (en) | 2017-11-06 | 2025-01-14 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| EP3707160A1 (en) | 2017-11-10 | 2020-09-16 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting tumor antigens |
| WO2019099483A1 (en) * | 2017-11-14 | 2019-05-23 | Memorial Sloan-Kettering Cancer Center | Il-36 secreting immunoresponsive cells and uses thereof |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| SG11202005217VA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods |
| WO2019113557A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CA3086832A1 (en) | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| CN110028588A (zh) * | 2018-01-11 | 2019-07-19 | 上海细胞治疗研究院 | 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用 |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| AU2019209428B2 (en) | 2018-01-22 | 2025-06-26 | Endocyte, Inc. | Methods of use for CAR T cells |
| CN108103027B (zh) * | 2018-02-02 | 2021-12-24 | 中国医学科学院血液病医院（血液学研究所） | 高效率血细胞重编程同时实现基因编辑的方法 |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN108383914A (zh) * | 2018-02-23 | 2018-08-10 | 北京美康基免生物科技有限公司 | 一种基于cd19的嵌合抗原受体及其应用 |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| JP2021515576A (ja) * | 2018-03-16 | 2021-06-24 | イミュソフト コーポレーション | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US10703733B2 (en) | 2018-05-14 | 2020-07-07 | Gilead Sciences, Inc. | MCL-1 inhibitors |
| SG11202011392VA (en) * | 2018-05-15 | 2020-12-30 | Carsgen Therapeutics Co Ltd | Genetically engineered cell and application thereof |
| EP3793575A4 (en) * | 2018-05-15 | 2022-01-19 | Case Western Reserve University | T-CELLS EXPRESSING LONG-LIVING CHIMERIC ANTIGEN RECEPTOR (CAR) FOR CANCER THERAPY |
| EP3841124A4 (en) | 2018-06-29 | 2022-03-23 | ApitBio, Inc. | ANTI-L1CAM ANTIBODIES AND USES THEREOF |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| CA3108657A1 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| US12497611B2 (en) | 2018-08-17 | 2025-12-16 | Yale University | Compositions and methods for high-throughput activation screening to boost T cell effector function |
| CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CA3110858A1 (en) * | 2018-08-31 | 2020-03-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions comprising b7h3 chimeric antigen receptors |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| JP7152080B2 (ja) * | 2018-10-19 | 2022-10-12 | カーテクセル インコーポレイテッド | 抗ｌ１ｃａｍ抗体又はその抗原結合断片、融合タンパク質、キメラ抗原受容体ポリペプチド、核酸分子、組換えベクター、効果器細胞、及び薬剤学的組成物 |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| MX2021005024A (es) | 2018-11-01 | 2021-07-21 | Juno Therapeutics Inc | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. |
| KR20210125978A (ko) | 2018-11-01 | 2021-10-19 | 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 | T 세포 조작을 위한 조성물 및 방법 |
| AU2019381526B2 (en) | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
| SG11202105084VA (en) * | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| CA3120364A1 (en) * | 2018-11-30 | 2020-06-04 | Celularity Inc. | Placenta-derived allogeneic car-t cells and uses thereof |
| FI3886875T3 (fi) * | 2018-11-30 | 2024-07-23 | Juno Therapeutics Inc | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä |
| ES2986007T3 (es) * | 2018-11-30 | 2024-11-08 | Juno Therapeutics Inc | Métodos para la dosificación y el tratamiento de neoplasias malignas de linfocitos B en terapia celular adoptiva |
| AU2019401282A1 (en) * | 2018-12-20 | 2021-07-15 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| CN113365660A (zh) | 2019-01-29 | 2021-09-07 | 朱诺治疗学股份有限公司 | 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US20200297768A1 (en) * | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| US20200308248A1 (en) * | 2019-03-26 | 2020-10-01 | ST Phi Therapeutics | Chimeric Natural Killer Cell Receptors and Method of Using Thereof |
| EP3953383A4 (en) * | 2019-04-08 | 2023-01-18 | Russell Biotech, Inc. | Improved manufacturing procedures for cell based therapies |
| CN109994156A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含报告模板信息管理模块的精准用药智能报告系统 |
| CN110010222A (zh) * | 2019-04-16 | 2019-07-12 | 长沙三济生物科技有限公司 | 一种基于精准用药知识库的基因身份识别系统 |
| CN109872792A (zh) * | 2019-04-16 | 2019-06-11 | 北京中佰耀因医药科技有限公司 | 一种用于指导精准用药的基因检测智能报告系统 |
| CN110010200A (zh) * | 2019-04-16 | 2019-07-12 | 长沙三济生物科技有限公司 | 一种基因身份识别系统 |
| CN109979545A (zh) * | 2019-04-16 | 2019-07-05 | 北京中佰耀因医药科技有限公司 | 一种含样本状态信息管理模块的精准用药智能报告系统 |
| CN109994176A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含样本类型信息管理模块的精准用药智能报告系统 |
| CN109994180A (zh) * | 2019-04-16 | 2019-07-09 | 北京中佰耀因医药科技有限公司 | 一种含基因位点信息管理模块的精准用药智能报告系统 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| WO2020247837A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| US20210030795A1 (en) * | 2019-06-17 | 2021-02-04 | Enochian BioPharma, Inc. | Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity |
| CA3143108A1 (en) * | 2019-06-19 | 2020-12-24 | Julius-Maximilians-Universitat Wurzburg | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| CN110608991B (zh) * | 2019-09-09 | 2022-04-29 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术的细胞周期检测试剂盒及检测方法 |
| MX2022004370A (es) | 2019-10-18 | 2022-05-06 | Forty Seven Inc | Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda. |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| JP7711068B2 (ja) | 2019-12-24 | 2025-07-22 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN111533808B (zh) * | 2020-03-10 | 2021-02-09 | 南京医科大学 | 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用 |
| WO2021189008A1 (en) | 2020-03-20 | 2021-09-23 | Lyell Immunopharma, Inc. | Novel recombinant cell surface markers |
| CR20220547A (es) | 2020-05-01 | 2022-12-15 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 |
| GB202007169D0 (en) * | 2020-05-14 | 2020-07-01 | Ospedale San Raffaele Srl | Epidermal growth factor receptor |
| EP3915575A1 (en) * | 2020-05-29 | 2021-12-01 | Imnate Sarl | Vaccine formulations |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| AU2021288464A1 (en) * | 2020-06-08 | 2023-01-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-CD171 chimeric antigen receptors |
| CN115701999A (zh) * | 2020-07-09 | 2023-02-14 | 南京传奇生物科技有限公司 | 用白介素-36工程化γδT细胞用于免疫疗法 |
| CA3188656A1 (en) | 2020-07-17 | 2022-01-20 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| WO2022125387A1 (en) * | 2020-12-08 | 2022-06-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2022155526A2 (en) * | 2021-01-15 | 2022-07-21 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Hybrid and truncated immune cell proteins |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN118056012B (zh) * | 2021-08-24 | 2025-05-30 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| KR20240099259A (ko) | 2021-10-14 | 2024-06-28 | 아스널 바이오사이언시스, 인크. | 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4667056A1 (en) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023173137A1 (en) * | 2022-03-11 | 2023-09-14 | Yale University | Compositions and methods for efficient and stable genetic modification of eukaryotic cells |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US20250255959A1 (en) * | 2022-04-01 | 2025-08-14 | Miltenyi Biotec B.V. & Co. KG | A system for drug-inducible expression of a polynucleotide |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN114990069B (zh) * | 2022-05-17 | 2023-09-22 | 郑州大学第一附属医院 | 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用 |
| EP4532701A1 (en) * | 2022-05-27 | 2025-04-09 | Autolus Limited | Method |
| PY2342670A (es) * | 2022-06-10 | 2023-12-19 | Joint Stock Company Biocad | Ácido nucleico con actividad promotora y uso del mismo |
| WO2024006702A1 (en) * | 2022-06-27 | 2024-01-04 | Foundation Medicine, Inc. | Methods and systems for predicting genotypic calls from whole-slide images |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| WO2024129984A1 (en) * | 2022-12-15 | 2024-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Homology-independent targeted dna insertion in human t cells |
| JP2025542256A (ja) * | 2022-12-20 | 2025-12-25 | アバタ セラピューティクス， インコーポレイテッド | １型糖尿病のための細胞療法 |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024153036A1 (zh) * | 2023-01-19 | 2024-07-25 | 武汉昭智生物技术有限公司 | 一种car分子、包含其的细胞或外泌体及它们的应用 |
| US20240290628A1 (en) * | 2023-02-24 | 2024-08-29 | American Air Liquide, Inc. | Etching method using oxygen-containing hydrofluorocarbon |
| JP2026507228A (ja) | 2023-03-03 | 2026-02-27 | アーセナル バイオサイエンシズ インコーポレイテッド | Ｐｓｍａ及びｃａ９を標的とするシステム |
| EP4695260A1 (en) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN116844685B (zh) * | 2023-07-03 | 2024-04-12 | 广州默锐医药科技有限公司 | 一种免疫治疗效果评估方法、装置、电子设备及存储介质 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024300557A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025207642A1 (en) * | 2024-03-25 | 2025-10-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Cxcr3 isoforms to improve recombinant receptor trafficking |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0557459T3 (da) | 1990-11-13 | 1997-12-15 | Immunex Corp | Bifunktionelle, selekterbare fusionsgener |
| US20020111474A1 (en) * | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| EP0650367A4 (en) | 1992-06-01 | 1998-04-15 | New England Medical Center Inc | BLOCKING OF INTERCELLULAR INTERACTIONS WITH CD43 CHEMICAL MOLECULES. |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| US6660257B1 (en) * | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| WO2000023573A2 (en) * | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US20040037816A1 (en) | 1999-04-15 | 2004-02-26 | Monash University | Graft acceptance through manipulation of thymic regeneration |
| US6912492B1 (en) * | 1999-05-25 | 2005-06-28 | University Of Medicine & Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
| JP4045713B2 (ja) | 2000-01-31 | 2008-02-13 | 松下電器産業株式会社 | 自動機用溶接機 |
| GB0015119D0 (en) * | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| AU2001270252B2 (en) | 2000-07-03 | 2007-02-08 | Catalent Pharma Solutions, Llc | Expression vectors |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| CA2425862C (en) | 2000-11-07 | 2013-01-22 | City Of Hope | Cd19-specific redirected immune cells |
| KR100900176B1 (ko) * | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) * | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| EP1397382B1 (en) | 2001-05-31 | 2008-08-06 | Novartis AG | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| WO2003025228A1 (en) * | 2001-09-18 | 2003-03-27 | Proteologics, Inc. | Methods and compositions for treating hcap associated diseases |
| US20030148982A1 (en) * | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| PL375033A1 (en) | 2002-04-11 | 2005-11-14 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
| US20040115814A1 (en) | 2002-09-30 | 2004-06-17 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| ATE472338T1 (de) * | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| US20050129671A1 (en) * | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20060160090A1 (en) | 2003-04-11 | 2006-07-20 | Macina Robert A | Composition splice variants and methods relating to cancer specific genes and proteins |
| CN1809277A (zh) * | 2003-04-18 | 2006-07-26 | 诺伍德免疫学有限公司 | 先于胸腺再活化的移植物耐受 |
| US20070166318A1 (en) | 2003-05-30 | 2007-07-19 | Macina Roberto A | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| NZ544543A (en) | 2003-07-21 | 2009-03-31 | Angeletti P Ist Richerche Bio | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| CA2543329A1 (en) | 2003-10-24 | 2005-05-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Orthogonal gene switches |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US8071364B2 (en) * | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) * | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| DE202005002921U1 (de) | 2005-02-23 | 2005-04-21 | Magcode Ag | Verbindungssystem, insbesondere elektrisches Verbindungssystem |
| EP1890708A4 (en) | 2005-06-01 | 2009-07-15 | Biotec Inst For Internat | GLUCOSE INDUCIBLE INSULIN EXPRESSION AND METHODS OF TREATING DIABETES |
| RU2008129827A (ru) | 2005-12-21 | 2010-01-27 | МЕДИММЬЮН, ЭлЭлСи (US) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ |
| NZ572884A (en) | 2006-05-22 | 2011-12-22 | Hiprocell Llc | Transformation of eukaryotic cells using two different recombination sites recognised by two different unidirectional site-specific recombinases |
| US8148129B2 (en) | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
| WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| EP2587263A1 (en) * | 2007-07-25 | 2013-05-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Self coupling recombinant antibody fusion proteins |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2346995B1 (en) * | 2008-09-26 | 2018-11-07 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| US20100332417A1 (en) | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| US9873035B2 (en) * | 2009-07-09 | 2018-01-23 | Cfph, Llc | Amusement device for a game of chance involving one or more rolling indicators on a rotating element with position indicators |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| JP5934099B2 (ja) | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| ES2717629T3 (es) * | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| BR112013018311A2 (pt) | 2011-01-18 | 2017-03-21 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada. |
| RU2688185C2 (ru) * | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
| JP2014514927A (ja) * | 2011-04-13 | 2014-06-26 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| WO2012167192A2 (en) | 2011-06-01 | 2012-12-06 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| KR102038155B1 (ko) | 2011-06-22 | 2019-10-29 | 에프. 호프만-라 로슈 아게 | Mhc 클래스 i 포함 복합체를 사용한 순환 바이러스-특이적 세포독성 t-세포에 의한 표적 세포의 제거 |
| CA2851795C (en) | 2011-10-20 | 2018-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| ITRM20120058A1 (it) * | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| AU2013222288A1 (en) * | 2012-02-22 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Use of ICOS-based CARs to enhance antitumor activity and CAR persistence |
| EA201990959A1 (ru) | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| JP2015523860A (ja) | 2012-05-30 | 2015-08-20 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | ＤＮＡの修復、変更および置き換えのための道具としてのスーパーコイルＭｉｎｉＶｅｃｔｏｒ |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| JP6079775B2 (ja) | 2012-06-01 | 2017-02-15 | 日本電気株式会社 | スイッチングシステム、ラインカード、スイッチカード、ｆｄｂ学習方法、ｆｄｂ学習調停方法及びプログラム |
| KR102264290B1 (ko) * | 2012-08-20 | 2021-06-10 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법을 위한 방법 및 조성물 |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| CN112458057A (zh) | 2012-10-02 | 2021-03-09 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014055771A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| WO2014099671A1 (en) * | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| EP2964753B1 (en) | 2013-03-07 | 2018-04-25 | Baylor College of Medicine | Targeting cd138 in cancer |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| NZ758715A (en) | 2013-10-31 | 2023-01-27 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| SG11201603484PA (en) | 2013-11-21 | 2016-05-30 | Ucl Business Plc | Cell |
| EP3808410A1 (en) | 2013-12-20 | 2021-04-21 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| WO2015095684A1 (en) | 2013-12-20 | 2015-06-25 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| CN107074957B (zh) | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CA2931979A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding properties |
| CN106414748B (zh) | 2014-02-14 | 2021-05-28 | 得克萨斯州大学系统董事会 | 嵌合抗原受体及制备方法 |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| CN112877291A (zh) * | 2014-04-10 | 2021-06-01 | 西雅图儿童医院 (Dba西雅图儿童研究所) | 基因修饰的t细胞产品、其制备方法和用途 |
| US10604740B2 (en) | 2014-05-14 | 2020-03-31 | Carsgen Therapeutics Limited | Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein |
| EP3149044B1 (en) | 2014-06-02 | 2020-10-21 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting cd-19 |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| KR102357004B1 (ko) | 2014-10-27 | 2022-01-27 | 프레드 헛친슨 켄서 리서치 센터 | 입양 세포 면역요법의 효능을 강화하기 위한 조성물 및 방법 |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| EP4272757A3 (en) | 2015-06-10 | 2023-12-27 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| CN108603170A (zh) | 2015-06-12 | 2018-09-28 | 莱蒂恩技术公司 | 用工程改造的t细胞治疗癌症的方法 |
| HK1256087A1 (zh) | 2015-08-07 | 2019-09-13 | Seattle Children's Hospital, Dba Seattle Children's Research Institute | 用於实体瘤靶向的双特异性cart细胞 |
| KR20180105709A (ko) | 2016-02-05 | 2018-09-28 | 시티 오브 호프 | 중추 신경계의 암의 치료를 위한 조작된 t 세포의 투여 |
| WO2017172952A1 (en) | 2016-04-01 | 2017-10-05 | Promab Biotechnologies, Inc. | Flag tagged cd19-car-t cells |
| EP3518972B1 (en) | 2016-09-28 | 2024-12-25 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
| ES2811500T3 (es) | 2016-10-04 | 2021-03-12 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células genéticamente modificadas |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| EP3833363A4 (en) | 2018-08-06 | 2022-05-11 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | METHODS AND COMPOSITIONS FOR STIMULATING CHIMERIC ANTIGEN RECEPTOR T-CELLS WITH HAPTEN-TAGGED CELLS |
| US10714296B2 (en) | 2018-12-12 | 2020-07-14 | Axcelis Technologies, Inc. | Ion source with tailored extraction shape |
| US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2015
- 2015-04-08 CN CN202110101875.0A patent/CN112877291A/zh active Pending
- 2015-04-08 KR KR1020237007831A patent/KR102730216B1/ko active Active
- 2015-04-08 WO PCT/US2015/024868 patent/WO2015157386A1/en not_active Ceased
- 2015-04-08 BR BR112016023500-2A patent/BR112016023500B1/pt not_active IP Right Cessation
- 2015-04-08 MY MYPI2016703719A patent/MY185678A/en unknown
- 2015-04-08 SG SG10201808825XA patent/SG10201808825XA/en unknown
- 2015-04-08 BR BR112016023517A patent/BR112016023517A2/pt not_active Application Discontinuation
- 2015-04-08 EP EP21180797.9A patent/EP3954708A1/en active Pending
- 2015-04-08 EP EP22151326.0A patent/EP4056201A1/en not_active Withdrawn
- 2015-04-08 ES ES15777065T patent/ES2880932T3/es active Active
- 2015-04-08 AU AU2015243920A patent/AU2015243920B2/en not_active Ceased
- 2015-04-08 CN CN201580030814.2A patent/CN106536558A/zh active Pending
- 2015-04-08 RU RU2016143385A patent/RU2751921C2/ru active
- 2015-04-08 NZ NZ725079A patent/NZ725079A/en not_active IP Right Cessation
- 2015-04-08 JP JP2016561839A patent/JP2017515464A/ja active Pending
- 2015-04-08 AU AU2015243922A patent/AU2015243922B2/en active Active
- 2015-04-08 KR KR1020167031070A patent/KR102509481B1/ko active Active
- 2015-04-08 MY MYPI2016703722A patent/MY192522A/en unknown
- 2015-04-08 PH PH1/2016/502011A patent/PH12016502011B1/en unknown
- 2015-04-08 AU AU2015243882A patent/AU2015243882C1/en not_active Ceased
- 2015-04-08 CA CA2945320A patent/CA2945320A1/en active Pending
- 2015-04-08 SG SG10201808811QA patent/SG10201808811QA/en unknown
- 2015-04-08 MY MYPI2016703721A patent/MY184163A/en unknown
- 2015-04-08 WO PCT/US2015/024866 patent/WO2015157384A1/en not_active Ceased
- 2015-04-08 KR KR1020167031069A patent/KR20160144431A/ko not_active Abandoned
- 2015-04-08 SG SG10201808833XA patent/SG10201808833XA/en unknown
- 2015-04-08 RU RU2016143381A patent/RU2752275C2/ru active
- 2015-04-08 SG SG11201608396YA patent/SG11201608396YA/en unknown
- 2015-04-08 EP EP15776211.3A patent/EP3129053A4/en not_active Withdrawn
- 2015-04-08 EP EP15776745.0A patent/EP3129405B1/en active Active
- 2015-04-08 IL IL297591A patent/IL297591B2/en unknown
- 2015-04-08 RU RU2016143384A patent/RU2729112C2/ru active
- 2015-04-08 BR BR112016023523A patent/BR112016023523A2/pt not_active Application Discontinuation
- 2015-04-08 CN CN201580027077.0A patent/CN106573969B/zh active Active
- 2015-04-08 AU AU2015243849A patent/AU2015243849B2/en not_active Ceased
- 2015-04-08 US US15/302,449 patent/US20170029774A1/en not_active Abandoned
- 2015-04-08 IL IL248238A patent/IL248238B2/en unknown
- 2015-04-08 SG SG11201608395PA patent/SG11201608395PA/en unknown
- 2015-04-08 EP EP15777020.7A patent/EP3129471A4/en active Pending
- 2015-04-08 KR KR1020227038237A patent/KR102618955B1/ko active Active
- 2015-04-08 CN CN201580030056.4A patent/CN106574246A/zh active Pending
- 2015-04-08 MX MX2016013149A patent/MX2016013149A/es unknown
- 2015-04-08 PH PH1/2016/502010A patent/PH12016502010B1/en unknown
- 2015-04-08 JP JP2016561722A patent/JP6772068B2/ja active Active
- 2015-04-08 SG SG10201808819XA patent/SG10201808819XA/en unknown
- 2015-04-08 WO PCT/US2015/024882 patent/WO2015157391A1/en not_active Ceased
- 2015-04-08 AU AU2015243927A patent/AU2015243927B2/en not_active Ceased
- 2015-04-08 KR KR1020167031064A patent/KR102463529B1/ko active Active
- 2015-04-08 MX MX2016013160A patent/MX387465B/es unknown
- 2015-04-08 WO PCT/US2015/024947 patent/WO2015157432A1/en not_active Ceased
- 2015-04-08 RU RU2016143389A patent/RU2016143389A/ru not_active Application Discontinuation
- 2015-04-08 RU RU2016143388A patent/RU2751920C2/ru active
- 2015-04-08 EP EP15776501.7A patent/EP3129480A4/en active Pending
- 2015-04-08 WO PCT/US2015/024895 patent/WO2015157399A1/en not_active Ceased
- 2015-04-08 CN CN201580029752.3A patent/CN106535934A/zh active Pending
- 2015-04-08 JP JP2016561635A patent/JP6765967B2/ja active Active
- 2015-04-08 SG SG11201608393TA patent/SG11201608393TA/en unknown
- 2015-04-08 IL IL248243A patent/IL248243B2/en unknown
- 2015-04-08 KR KR1020227011931A patent/KR102600544B1/ko active Active
- 2015-04-08 JP JP2017504604A patent/JP6788573B6/ja active Active
- 2015-04-08 MY MYPI2016703720A patent/MY186846A/en unknown
- 2015-04-08 MX MX2016013144A patent/MX395574B/es unknown
- 2015-04-08 CN CN202110842538.7A patent/CN113528581A/zh active Pending
- 2015-04-08 CN CN201580030815.7A patent/CN106661570B/zh active Active
- 2015-04-08 KR KR1020167031067A patent/KR102508166B1/ko active Active
- 2015-04-08 EP EP21175647.3A patent/EP3943507A1/en not_active Withdrawn
- 2015-04-08 US US15/302,415 patent/US10266592B2/en active Active
- 2015-04-08 EP EP15777065.2A patent/EP3129399B1/en active Active
- 2015-04-08 PH PH1/2016/502009A patent/PH12016502009B1/en unknown
- 2015-04-08 US US15/302,403 patent/US10865242B2/en active Active
- 2015-04-08 MX MX2016013159A patent/MX389797B/es unknown
- 2015-04-08 CA CA2945305A patent/CA2945305C/en active Active
- 2015-04-08 SG SG11201608392WA patent/SG11201608392WA/en unknown
- 2015-04-08 JP JP2016561659A patent/JP6765968B2/ja active Active
- 2015-04-08 CA CA2945308A patent/CA2945308C/en active Active
- 2015-04-08 ES ES15776745T patent/ES2867224T3/es active Active
- 2015-04-08 NZ NZ725081A patent/NZ725081A/en not_active IP Right Cessation
- 2015-04-08 CA CA2945303A patent/CA2945303C/en active Active
- 2015-04-08 KR KR1020167031068A patent/KR102387243B1/ko active Active
- 2015-04-08 MX MX2016013158A patent/MX2016013158A/es unknown
- 2015-04-08 US US15/302,420 patent/US10611837B2/en active Active
- 2015-04-08 US US15/302,426 patent/US20170015746A1/en not_active Abandoned
- 2015-04-08 NZ NZ73944815A patent/NZ739448A/en not_active IP Right Cessation
-
2016
- 2016-10-06 IL IL248229A patent/IL248229B2/en unknown
- 2016-10-06 MX MX2022010807A patent/MX2022010807A/es unknown
- 2016-10-06 IL IL248235A patent/IL248235B/en active IP Right Grant
- 2016-10-10 PH PH12016502012A patent/PH12016502012A1/en unknown
- 2016-10-10 SA SA516380056A patent/SA516380056B1/ar unknown
- 2016-10-13 ZA ZA2016/07060A patent/ZA201607060B/en unknown
- 2016-10-13 ZA ZA2016/07053A patent/ZA201607053B/en unknown
- 2016-10-13 ZA ZA2016/07061A patent/ZA201607061B/en unknown
-
2019
- 2019-02-27 US US16/287,074 patent/US11155616B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/794,673 patent/US11414486B2/en active Active
- 2020-06-18 JP JP2020105133A patent/JP7062720B2/ja active Active
- 2020-09-16 JP JP2020155809A patent/JP7093385B2/ja not_active Expired - Fee Related
- 2020-09-16 JP JP2020155429A patent/JP7148580B2/ja active Active
- 2020-09-30 JP JP2020164326A patent/JP7106610B2/ja active Active
- 2020-11-12 US US17/096,138 patent/US12258397B2/en active Active
- 2020-11-13 US US17/097,630 patent/US20210371517A1/en active Pending
-
2021
- 2021-01-04 AU AU2021200007A patent/AU2021200007B2/en not_active Ceased
- 2021-03-17 AU AU2021201679A patent/AU2021201679B2/en not_active Ceased
- 2021-09-10 US US17/472,284 patent/US12202897B2/en active Active
- 2021-11-26 AU AU2021273652A patent/AU2021273652A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069142A patent/JP7542270B2/ja active Active
- 2022-04-21 US US17/660,114 patent/US12503507B2/en active Active
- 2022-07-13 JP JP2022112278A patent/JP7402933B2/ja active Active
- 2022-07-15 US US17/812,848 patent/US12448445B2/en active Active
- 2022-09-22 JP JP2022150928A patent/JP7508516B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021019589A5 (enExample) | ||
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| US10766943B2 (en) | Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| Han et al. | Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges | |
| KR102308597B1 (ko) | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 | |
| CN104822705B (zh) | M971嵌合抗原受体 | |
| FI3824905T3 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2018523485A5 (enExample) | ||
| JP2019500894A5 (enExample) | ||
| JP2016534717A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2017513470A5 (enExample) | ||
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2016520074A5 (enExample) | ||
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017537627A5 (enExample) | ||
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| WO2017192536A1 (en) | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy | |
| JPWO2020051493A5 (enExample) | ||
| Alrifai et al. | Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells | |
| WO2020176897A1 (en) | Chimeric antigen receptors and uses thereof | |
| Li et al. | Genetically modified T-cells affinity to tumor cells-development of adoptive T-cell immunotherapy | |
| KR102689877B1 (ko) | CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 | |
| Krebs et al. | T cells redirected to IL13Rα2 with IL13 mutein-CARs have antiglioma activity but also recognize IL13Rα1 | |
| HK40109914A (zh) | 抗egfrviii抗体、多肽、表达前述多肽的细胞、包含前述细胞的医药组合物、前述细胞的制造方法、及包含编码前述多肽的碱基序列的多核苷酸或载体 |